relypsa_viforgroup_logo_medium_color (1).jpg
Relypsa Announces Third Quarter 2015 Financial Results
November 04, 2015 16:05 ET | Relypsa, Inc.
REDWOOD CITY, Calif., Nov. 04, 2015 (GLOBE NEWSWIRE) --  Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today reported financial results for the quarter ended September 30, 2015...
relypsa_viforgroup_logo_medium_color (1).jpg
Relypsa to Present at Two Upcoming Conferences
November 03, 2015 08:30 ET | Relypsa, Inc.
REDWOOD CITY, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that the company will present at two upcoming investor conferences in November 2015. John A....
relypsa_viforgroup_logo_medium_color (1).jpg
Relypsa Announces Data for Veltassa (patiromer) to be Presented at ASN Kidney Week 2015
October 29, 2015 16:30 ET | Relypsa, Inc.
OPAL-HK sub-group analysis in hyperkalemic chronic kidney disease (CKD) patients age 65 or older will be featured in oral presentation  Poster presentation will highlight data from OPAL-HK...
relypsa_viforgroup_logo_medium_color (1).jpg
RELYPSA ANNOUNCES FDA APPROVAL OF VELTASSA(TM) (PATIROMER) FOR ORAL SUSPENSION FOR THE TREATMENT OF HYPERKALEMIA
October 21, 2015 20:34 ET | Relypsa, Inc.
First new medicine for the treatment of hyperkalemia, or high blood potassium levels, in more than 50 years Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure...
relypsa_viforgroup_logo_medium_color (1).jpg
Relypsa Announces New Employment Inducement Grants
October 19, 2015 08:30 ET | Relypsa, Inc.
REDWOOD CITY, Calif., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on October 15, 2015, the compensation committee of the...
relypsa_viforgroup_logo_medium_color (1).jpg
European Journal of Heart Failure Publishes Pre-Specified Sub-Group Analysis of Heart Failure Patients With Hyperkalemia From Phase 3 Trial of Patiromer FOS
October 13, 2015 16:30 ET | Relypsa, Inc.
Pre-specified sub-group analysis from OPAL-HK trial of hyperkalemic chronic kidney disease (CKD) patients with heart failure receiving renin angiotensin aldosterone system (RAAS) inhibitor therapy...
relypsa_viforgroup_logo_medium_color (1).jpg
Relypsa Announces New Employment Inducement Grants
October 02, 2015 08:30 ET | Relypsa, Inc.
REDWOOD CITY, Calif., Oct. 2, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on October 1, 2015, the compensation committee of the company's...
relypsa_viforgroup_logo_medium_color (1).jpg
Relypsa Announces New Employment Inducement Grants
September 21, 2015 08:30 ET | Relypsa, Inc.
REDWOOD CITY, Calif., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on September 15, 2015, the compensation committee of the...
relypsa_viforgroup_logo_medium_color (1).jpg
Relypsa Announces Publication of Patiromer FOS Onset-of-Action Study in Kidney International
September 16, 2015 16:43 ET | Relypsa, Inc.
Study to establish onset of action, conducted in diet-controlled patients with chronic kidney disease and moderate-to-severe hyperkalemia, taking RAAS inhibitor therapy Patiromer FOS...
relypsa_viforgroup_logo_medium_color (1).jpg
Relypsa Announces New Employment Inducement Grants
September 04, 2015 08:30 ET | Relypsa, Inc.
REDWOOD CITY, Calif., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on September 1, 2015, the compensation committee of the company's...